At a glance
ClinicalIndex Comparison RecordN/ACompleted· 284 enrolled
Drug / intervention
Lopinavir/Ritonavir (Kaletra)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Kaletra Therapy Over the Long-term
In Brief
An observational study evaluating Lopinavir/Ritonavir (Kaletra) for Human Immunodeficiency Virus. Completed, enrolled 284 participants across 90 sites.
Detailed Summary
Long term observation of patients under lopinavir/ritonavir containing therapy
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Immunodeficiency Virus
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2001
First PostedMar 2010
Primary CompletionJun 2010
TodayJul 2026
First PostedMar 10, 2010
Enrollment StartJun 1, 2001
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 9 yearsPosted 16.3 years ago
Interventions
Lopinavir/Ritonavir (Kaletra)drug
3 capsules 2xdaily or 2 tablets 2xdaily Kaletra